BR112019012203A2 - marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile - Google Patents
marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficileInfo
- Publication number
- BR112019012203A2 BR112019012203A2 BR112019012203-6A BR112019012203A BR112019012203A2 BR 112019012203 A2 BR112019012203 A2 BR 112019012203A2 BR 112019012203 A BR112019012203 A BR 112019012203A BR 112019012203 A2 BR112019012203 A2 BR 112019012203A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- tcdb
- response
- clostridium difficile
- genetic markers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1282—Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/109900 WO2018107388A1 (en) | 2016-12-14 | 2016-12-14 | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
| US201762508066P | 2017-05-18 | 2017-05-18 | |
| PCT/US2017/064985 WO2018111662A1 (en) | 2016-12-14 | 2017-12-07 | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019012203A2 true BR112019012203A2 (pt) | 2019-11-12 |
Family
ID=62559092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012203-6A BR112019012203A2 (pt) | 2016-12-14 | 2017-12-07 | marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12071666B2 (https=) |
| EP (1) | EP3555303B1 (https=) |
| JP (3) | JP2020502179A (https=) |
| CN (1) | CN110088300A (https=) |
| AU (1) | AU2017375590A1 (https=) |
| BR (1) | BR112019012203A2 (https=) |
| MX (1) | MX2019007012A (https=) |
| RU (1) | RU2761249C2 (https=) |
| WO (1) | WO2018111662A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12071666B2 (en) * | 2016-12-14 | 2024-08-27 | Merck Sharp & Dohme Llc | Human genetic markers associated with response to treatments that target clostridium difficile toxin B |
| CN112481395B (zh) * | 2019-09-12 | 2024-10-18 | 深圳华大生命科学研究院 | 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA2044591C (en) | 1989-02-13 | 2002-08-13 | James Langham Dale | Detection of a nucleic acid sequence or a change therein |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| EP0754240B1 (en) | 1994-02-07 | 2003-08-20 | Beckman Coulter, Inc. | Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| AU710425B2 (en) | 1995-12-18 | 1999-09-23 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| ES2215241T3 (es) | 1996-11-06 | 2004-10-01 | Sequenom, Inc. | Procedimiento de espectrometria de masa. |
| DE19782097T1 (de) | 1996-11-06 | 1999-10-14 | Sequenom Inc | Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger |
| JP2010522560A (ja) * | 2007-03-27 | 2010-07-08 | デューク ユニバーシティ | Ｈｉｖ疾患制限に関連する遺伝的変異体 |
| US20100035265A1 (en) | 2008-07-18 | 2010-02-11 | Aris Floratos | Biomarkers for Drug-Induced Liver Injury |
| WO2010050829A1 (en) | 2008-10-31 | 2010-05-06 | Vialactia Biosciences (Nz) Limited | Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype |
| PE20120056A1 (es) | 2009-02-24 | 2012-02-05 | Merck Sharp & Dohme | Derivados de indol como antagonistas del receptor crth2 |
| HUE029098T2 (en) * | 2009-08-21 | 2017-02-28 | Novartis Ag | To treat lapatinib cancer |
| SG10201701055WA (en) * | 2011-09-16 | 2017-03-30 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| US10280470B2 (en) * | 2013-01-11 | 2019-05-07 | Baylor College Of Medicine | Biomarkers of recurrent Clostridium difficile infection |
| EP3004386B1 (en) * | 2013-05-29 | 2019-08-07 | Immunexpress Pty Ltd | Microbial markers and uses therefor |
| US9181632B1 (en) * | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
| CN103665141B (zh) * | 2013-12-31 | 2015-09-16 | 北京大学 | 与艰难梭菌细胞毒素b相互作用的蛋白 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| US12071666B2 (en) * | 2016-12-14 | 2024-08-27 | Merck Sharp & Dohme Llc | Human genetic markers associated with response to treatments that target clostridium difficile toxin B |
| WO2018107388A1 (en) | 2016-12-14 | 2018-06-21 | Merck Sharp & Dohme Corp. | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
-
2017
- 2017-12-07 US US16/468,982 patent/US12071666B2/en active Active
- 2017-12-07 CN CN201780077861.1A patent/CN110088300A/zh active Pending
- 2017-12-07 JP JP2019532806A patent/JP2020502179A/ja active Pending
- 2017-12-07 MX MX2019007012A patent/MX2019007012A/es unknown
- 2017-12-07 RU RU2019122099A patent/RU2761249C2/ru active
- 2017-12-07 EP EP17881986.8A patent/EP3555303B1/en active Active
- 2017-12-07 BR BR112019012203-6A patent/BR112019012203A2/pt active Search and Examination
- 2017-12-07 WO PCT/US2017/064985 patent/WO2018111662A1/en not_active Ceased
- 2017-12-07 AU AU2017375590A patent/AU2017375590A1/en not_active Abandoned
-
2022
- 2022-12-29 JP JP2022212848A patent/JP2023055222A/ja active Pending
-
2025
- 2025-01-08 JP JP2025002966A patent/JP2025061120A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3555303A4 (en) | 2020-06-24 |
| AU2017375590A1 (en) | 2019-06-13 |
| CN110088300A (zh) | 2019-08-02 |
| MX2019007012A (es) | 2019-11-28 |
| RU2019122099A3 (https=) | 2021-04-16 |
| JP2025061120A (ja) | 2025-04-10 |
| RU2019122099A (ru) | 2021-01-15 |
| JP2023055222A (ja) | 2023-04-17 |
| US20200017909A1 (en) | 2020-01-16 |
| WO2018111662A1 (en) | 2018-06-21 |
| EP3555303B1 (en) | 2022-12-21 |
| US12071666B2 (en) | 2024-08-27 |
| RU2761249C2 (ru) | 2021-12-06 |
| EP3555303A1 (en) | 2019-10-23 |
| JP2020502179A (ja) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022789A2 (pt) | Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a | |
| BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
| BR112017014341A2 (pt) | método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição. | |
| BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112017024928A2 (pt) | Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica | |
| BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| BR112018072560A2 (pt) | terapia de combinação para tratamento do câncer | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| BR112014020233A2 (pt) | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 | |
| BR112016014876A2 (pt) | composto que modula a quantidade ou a atividade de gibspla2, composição farmacêutica, imunógeno que induz uma resposta imune anti-gibspla2, composição de vacina, método para o diagnóstico da imunodeficiência humana associada com a alteração de células t, e, método para a produção de gibspla2 | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| National Collaborating Centre for Women's and Children's Health (UK | Bronchiolitis: diagnosis and management of bronchiolitis in children | |
| PT110171A (pt) | Método de treino da capacidade cognitiva com base emocional | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| WO2017192662A3 (en) | Methods for identifying treatment targets based on multiomics data | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| BR112017015060A2 (pt) | protocolos de tratamento térmico personalizados | |
| WO2017142895A8 (en) | Compositions and methods for treating clostridium associated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |